Literature DB >> 8314449

Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

F S Nielsen1, A I Voldsgaard, M A Gall, P Rossing, E Hommel, P Andersen, J Dyerberg, H H Parving.   

Abstract

The relative mortality from cardiovascular disease is on average increased five-fold in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy compared to non-diabetic subjects. We assessed the possible contribution of dyslipidaemia in general and elevated serum apolipoprotein(a) (apo(a)) in particular. Type 2 diabetic patients with normo-, micro- and macroalbuminuria were compared with healthy subjects. Each group consisted of 37 subjects matched for age, sex and diabetes duration. Serum creatinine in the nephropathy group was 105 (54-740) mumol/l. The prevalence of ischaemic heart disease (resting ECG, Minnesota, Rating Scale) was 57, 35, 19 and 2% in macro-, micro- and normoalbuminuric diabetic patients and healthy subjects, respectively. The prevalence of ischaemic heart disease was higher in all diabetic groups as compared to healthy subjects (p < 0.05), and higher in macroalbuminuric as compared to normoalbuminuric diabetic patients (p < 0.01). There was no significant difference between apo(a) in the four groups: 161 (10-1370), 191 (10-2080), 147 (10-942), 102 (10-1440) U/l (median (range)) in macro-, micro- and normoalbuminuric groups and healthy subjects. Serum total-cholesterol, HDL-cholesterol and LDL-cholesterol were not significantly different when comparing healthy subjects and each diabetic group. Apolipoprotein A-I was lower (p < 0.05) in all diabetic groups as compared to healthy subjects (nephropathy vs healthy subjects): 1.50 +/- 0.25 vs 1.69 +/- 0.32 g/l (mean +/- SD). Triglyceride was higher (p < 0.05) in patients with nephropathy and microalbuminuria as compared to healthy subjects (nephropathy vs healthy subjects): 2.01 (0.66-14.7) vs 1.09 (0.41-2.75) mmol/l (median (range)).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314449     DOI: 10.1007/bf00402281

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  [Fully mechanized kinetic measurement of creatinine].

Authors:  R Ullmann; K Bonitz
Journal:  Med Lab (Stuttg)       Date:  1976-06

2.  [Oscillometric determination of blood pressure].

Authors:  N Wiinberg; J Nygart; H Sengeløv; P E Nielsen
Journal:  Ugeskr Laeger       Date:  1988-05-23

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Multicentre study of a new enzymatic method of cholesterol determination.

Authors:  R Kattermann; D Jaworek; G Möller; G Assmann; I Björkhem; L Svensson; K Borner; G Boerma; B Leijnse; J P Desager
Journal:  J Clin Chem Clin Biochem       Date:  1984-03

5.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.

Authors:  L A Carlson; A Hamsten; A Asplund
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

6.  Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients.

Authors:  H H Parving; M A Gall; P Skøtt; H E Jørgensen; H Løkkegaard; F Jørgensen; B Nielsen; S Larsen
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

7.  Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin.

Authors:  I Karádi; L Romics; G Pálos; J Domán; I Kaszás; A Hesz; G M Kostner
Journal:  Clin Chem       Date:  1989-10       Impact factor: 8.327

8.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.

Authors:  M Rath; A Niendorf; T Reblin; M Dietel; H J Krebber; U Beisiegel
Journal:  Arteriosclerosis       Date:  1989 Sep-Oct

9.  Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy.

Authors:  M A Gall; P Rossing; E Hommel; A I Voldsgaard; P Andersen; F S Nielsen; J Dyerberg; H H Parving
Journal:  Scand J Clin Lab Invest       Date:  1992-10       Impact factor: 1.713

10.  Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria.

Authors:  H Kapelrud; H J Bangstad; K Dahl-Jørgensen; K Berg; K F Hanssen
Journal:  BMJ       Date:  1991-09-21
View more
  3 in total

1.  Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.

Authors:  K Hirata; K Saku; S Jimi; S Kikuchi; H Hamaguchi; K Arakawa
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

2.  Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes.

Authors:  J Ruiz; J Thillet; T Huby; R W James; D Erlich; P Flandre; P Froguel; J Chapman; P Passa
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

3.  Lipoprotein (a) and vascular disease in diabetic patients.

Authors:  R W James; M Boemi; C Sirolla; L Amadio; P Fumelli; D Pometta
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.